# Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies

> **NCT02504619** · PHASE1,PHASE2 · TERMINATED · sponsor: **Gamida Cell ltd** · enrollment: 1 (actual)

## Conditions studied

- Sickle Cell Disease
- Thalassemia

## Interventions

- **BIOLOGICAL:** CordIn

## Key facts

- **NCT ID:** NCT02504619
- **Lead sponsor:** Gamida Cell ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-04-04
- **Primary completion:** 2016-08
- **Final completion:** 2017-12
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** lack of recruitment
- **Last updated:** 2019-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02504619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02504619, "Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02504619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*